Lance Grady leads Avalere’s Market Access practice, devising commercialization strategies focused on value, access, and reimbursement.
In recent partnerships, Lance has helped life sciences companies develop commercialization and launch planning strategies, and drug pricing and positioning strategy to maximize commercial success, access, and coverage by CMS and in Medicare and commercial markets. Knowledge and experience in reimbursement policy, payment reform, and the application of data analytics are instrumental in his approach to informing strategy and quantifying impact across a multitude of stakeholders. At the intersection of clinical, reimbursement, and market access strategy, Lance has led the growth and transition of the Avalere Market Access practice providing extensive solutions along the product development cycle in preparation for launch and in response to market forces and policy changes in the US market.
Before joining Avalere, Lance spent 12 years at Bristol-Myers Squibb in various leadership roles focused on US market access. He has worked for more than 20 years devising access, policy, and reimbursement strategies, focusing on oncology and autoimmune disease and on orphan drug and cell and gene therapy markets.
Lance graduated from the University of Louisiana-Monroe, where he studied immunobiology.
In recent partnerships, Lance has helped life sciences companies develop commercialization and launch planning strategies, and drug pricing and positioning strategy to maximize commercial success, access, and coverage by CMS and in Medicare and commercial markets. Knowledge and experience in reimbursement policy, payment reform, and the application of data analytics are instrumental in his approach to informing strategy and quantifying impact across a multitude of stakeholders. At the intersection of clinical, reimbursement, and market access strategy, Lance has led the growth and transition of the Avalere Market Access practice providing extensive solutions along the product development cycle in preparation for launch and in response to market forces and policy changes in the US market.
Before joining Avalere, Lance spent 12 years at Bristol-Myers Squibb in various leadership roles focused on US market access. He has worked for more than 20 years devising access, policy, and reimbursement strategies, focusing on oncology and autoimmune disease and on orphan drug and cell and gene therapy markets.
Lance graduated from the University of Louisiana-Monroe, where he studied immunobiology.
Speaking In
4:15 PM - 5:15 PM
Wednesday, June 7
